Morgan Stanley Reiterates Overweight on Eli Lilly, Maintains $1106 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Terence Flynn has reiterated an Overweight rating on Eli Lilly (NYSE:LLY) and maintained a price target of $1106.

August 27, 2024 | 12:56 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley's analyst Terence Flynn has reiterated an Overweight rating on Eli Lilly, maintaining a price target of $1106. This suggests confidence in Eli Lilly's stock performance.
The reiteration of an Overweight rating and a high price target by a reputable analyst like Terence Flynn from Morgan Stanley indicates a positive outlook for Eli Lilly's stock. This can lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100